60561-28-6

Basic information

• Product Name: ethyl 5-acetyl-2-benzyloxybenzoate
• Synonyms: ethyl 5-acetyl-2-benzyloxybenzoate;5-Acetyl-2-(phenylmethoxy)benzoic acid ethyl ester;Einecs 262-297-5
• CAS NO: 60561-28-6
• Molecular Formula: C₁₈H₁₈O₄
• Molecular Weight: 298.33312
• EINECS: 262-297-5
• Mol File: 60561-28-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 454.5°C at 760 mmHg
• Flash Point: 200.8°C
• Appearance: /
• Density: 1.147g/cm³
• Vapor Pressure: 1.9E-08mmHg at 25°C
• Refractive Index: 1.558
• CAS DataBase Reference: ethyl 5-acetyl-2-benzyloxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-acetyl-2-benzyloxybenzoate(60561-28-6)
• EPA Substance Registry System: ethyl 5-acetyl-2-benzyloxybenzoate(60561-28-6)

Safety Data

• Hazardous Substances Data: 60561-28-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C18H18O4/c1-3-21-18(20)16-11-15(13(2)19)9-10-17(16)22-12-14-7-5-4-6-8-14/h4-11H,3,12H2,1-2H3

Upstream product

• 16475-93-7 5-acetyl-2-hydroxybenzoic acid ethyl ester 
• 100-44-7 benzyl chloride 

Downstream Products

• 92900-98-6 1-(4-Benzyloxy-3-hydroxymethyl-phenyl)-2-(4-diethylamino-6,7-dimethoxy-quinazolin-2-ylamino)-ethanol; hydrochloride 
• 92901-01-4 1-(4-Benzyloxy-3-hydroxymethyl-phenyl)-2-(2-diethylamino-6,7-dimethoxy-quinazolin-4-ylamino)-ethanol; hydrochloride 
• 92900-87-3 4-[2-(4-Diethylamino-6,7-dimethoxy-quinazolin-2-ylamino)-1-hydroxy-ethyl]-2-hydroxymethyl-phenol; hydrochloride 
• 92900-94-2 4-[2-(2-Diethylamino-6,7-dimethoxy-quinazolin-4-ylamino)-1-hydroxy-ethyl]-2-hydroxymethyl-phenol; hydrochloride 
• 92901-02-5 5-(2-Azido-acetyl)-2-benzyloxy-benzoic acid ethyl ester 
• 92900-77-1 α1-(aminomethyl)-4-(benzyloxy)-1,3-benzenedimethanol 
• 56443-71-1 ethyl 2-(bezyloxy)-5-(2-bromoacetyl)benzoate 

Relevant articles and documents

2-(β-Arylethylamino)- and 4-(β-Arylethylamino)quinazolines as Phosphodiesterase Inhibitors

The existence of several forms of cAMP phosphodiesterase having different kinetic characteristics suggests the feasibility of developing tissue-selective inhibitors of this enzyme.This observation is of particular importance in the development of therapeutic agents for the management of reversible obstructive airways disorders.The present report describes the design, synthesis and pharmacological characterization of a series of 6,7-dimethoxyquinazoline derivatives having β-arylethylamine substituents at the 2- or 4- positions.The quinazoline nucleus is intended to confer a high degree of inhibitory activity for phosphodiesterase while the β-arylethylamine moieties are designed to provide selectivity for adrenergically innervated tissue.The target compounds of this study, 6 and 7 were prepared via β-arylethylamine displacement of chloride from an appropriate chloroquinazoline intermediate.The resulting products were evaluated for their ability to relax guinea pig tracheal smooth muscle and as inhibitors of phosphodiesterase.